CMIC Co. Ltd - A Win-Win Outcome with CROs


Published on

Kazuo Nakamura from CMIC Co., Ltd., a sponsor company at the upcoming marcus evans Evolution Summit 2011 and Evolution Summit 2012, on maximising the CRO-pharmaceutical company relationship.

Interview with: Kazuo Nakamura, Chief Executive Officer, CMIC Co., Ltd.

Published in: Education, Business
  • Be the first to comment

  • Be the first to like this

No Downloads
Total views
On SlideShare
From Embeds
Number of Embeds
Embeds 0
No embeds

No notes for slide

CMIC Co. Ltd - A Win-Win Outcome with CROs

  1. 1. CMIC Co. Ltd -A Win-Win Outcome with CROs Kazuo Nakamura from CMIC Co., Ltd., a sponsor company at the upcoming marcus evans Evolution Summit 2011 and Evolution Summit 2012, on maximising the CRO-pharmaceutical company relationship. Interview with: Kazuo Nakamura, Chief Executive Officer, CMIC Co., Ltd.FOR IMMEDIATE RELEASE“The Contract Research Organisation (CRO) is a key part of times too complicated, hindering innovation. The governmentthe development of orphan drugs,” says Kazuo Nakamura, is very conservative and in some cases we have a very bigChief Executive Officer, CMIC Co., Ltd. When the profit documentation backlog. CMIC is trying to re-engineer thismargin is low, a CRO developing drugs for pharmaceutical process.companies results in a win-win outcome for both parties. What would help pharmaceutical companies maximise returnFrom a sponsor company at the upcoming marcus evans on investment?Evolution Summit 2011, in Montreux, Switzerland, 17 - 19October and Evolution Summit 2012, in North America, Kazuo Nakamura: Pharmaceutical companies need to formNakamura talks about maximising the CRO-pharmaceutical strategic partnerships with their CROs. Old-fashioned type ofcompany partnership, and his expectations for the coming outsourcing such as using them like one part of their companyyears. is no more productive.What insights do you have into what is challenging Chief Developing the new process to facilitate the trial with theirMedical Officers (CMOs) of pharmaceutical companies today? partnered CRO is essential to reduce the cost while maintaining the good level of trial quality and data integrity.Kazuo Nakamura: Some pharmaceutical companies want to From this point of view selecting the appropriate CRO andenter the orphan drug development market, yet they do not providing them with the information they need would be thehave the know-how. Licensing out in the Japanese market is key to success in developing the drug sooner. Closecomplicated and requires expertise and negotiating with local collaboration is necessary for a win-win situation.authorities. Many want to sell the drugs without heavilyinvesting into the development themselves. What are your expectations for the coming years?The pharmaceutical market in Asia holds great potential, Kazuo Nakamura: Lately translational research programs arewhich is why many large companies from across the world are increasing at the academic centres strongly backed up by thelooking into taking advantage of the opportunities the region governmental financial support in Japan. These programmeshas to offer. However, they cannot necessarily do it alone. are expected to prove the concept of the programme forCROs play a key role in this. future contribution to the patients.Asia is also attractive when it comes to recruiting a vast We, CROs, can play an important role to support their R&D innumber of patients for clinical trials; CROs can facilitate and terms of pre-clinical studies and clinical studies for thespeed up that process. targeted technologies in compliance with the necessary regulations.How can clinical trial safety and efficiency be enhanced? CMOs should carefully watch the result of these activities andKazuo Nakamura: CMIC is challenging the process of not lose the opportunity to license-in their technologies.innovation in drug development. Conducting clinical trials is at
  2. 2. Contact: Sarin Kouyoumdjian-Gurunlian, Press Manager, marcus evans, Summits DivisionTel: + 357 22 849 313Email: press@marcusevanscy.comFor more information please send an email to or visit the event websites below:Evolution Summit 2011 - Europe: www.evolution-summit.comEvolution Summit 2012 - North America: www.evolutionsummit.commarcus evans group - life sciences / pharma sector portalComplementing our summit format, the Pharma Network – marcus evans Summits group delivers peer-to-peerinformation on strategic matters, professional trends and breakthrough innovations. Lend an ear to fellow experts andlive news from our events on our LinkedIn and Twitter accounts!Please note that the summit is a closed business event and the number of participants strictly limited.About CMIC Co., LtdThe CMIC Group has been taking the lead in the industry since 1992 when it started the first ever CRO (ContractResearch Organization) business in Japan.Using its abundant experience, CMIC comprehensively supports pharmaceutical companies in carrying out their valuechains of drug development, manufacturing and marketing & marcus evans Summitsmarcus evans Summits are high level business forums for the world’s leading decision-makers to meet, learn anddiscuss strategies and solutions. Held at exclusive locations around the world, these events provide attendees with aunique opportunity to individually tailor their schedules of keynote presentations, think tanks, seminars and one-to-onebusiness meetings. For more information, please visit www.marcusevans.comAll rights reserved. The above content may be republished or reproduced – kindly inform us by sending an email to